Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Thursday 01 October, 2009

Lipoxen PLC

Issue of Equity

RNS Number : 0833A
Lipoxen PLC
01 October 2009
 



Lipoxen PLC

('Lipoxen' or 'the Company')


Additional listing and Total Voting Right


London, UK, 1 October 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 100,000 ordinary shares of 0.5p each (the 'New Ordinary Shares').


The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.


It is expected that dealings in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 2 October 2009.


In conformity with the FSA's Disclosure and Transparency Rules, the Company notifies the market of the following:


Following the admission to trading on AIM of the Ordinary Shares mentioned above Lipoxen's capital consists of 154,210,085 ordinary shares of 0.5p each ('Ordinary Shares') with voting rights. No Ordinary Shares are held in treasury, therefore the total number of voting rights in the Company is 154,210,085.


The above figure (154,210,085) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Lipoxen under the FSA's Disclosure and Transparency Rules.


Enquiries 

Lipoxen plc

+44 (0)20 7691 3583 

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 




Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  




Buchanan Communications

+44 (0)20 7466 5000

Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen




This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEBSBDGRGGGGCB